Navigation Links
Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke

r mini-stroke but no known coronary heart disease. In these patients, Lipitor significantly reduced the risk of coronary heart disease events by 43 percent compared with those taking placebo. The risk of stroke was reduced by 12 percent and major coronary events by 26 percent, but these results were not statistically significant.

"This analysis reminds us of the importance of managing patients' overall risk factors to reduce the risk of serious complications," said Dr. Welch.

About the SPARCL Study

The SPARCL study, published in the New England Journal of Medicine in 2006, is the only study to date evaluating statin therapy exclusively for patients with recent stroke or mini-stroke and no coronary heart disease (n=4,731). Lipitor 80 mg is the only statin to have shown stroke benefit in these patients. Lipitor 80 mg reduced the risk of an additional stroke by 16 percent and major coronary events by 35 percent compared with placebo. In a post-hoc analysis of the SPARCL trial, there was a higher incidence of hemorrhagic stroke in patients taking Lipitor 80 mg compared with patients taking placebo. Patients with prior hemorrhagic stroke at study entry appeared to be at an increased risk of hemorrhagic stroke.

In SPARCL, Lipitor was well tolerated. The rate of side effects such as elevated liver enzymes was low and consistent with the known safety profile and there was no difference in the incidence of muscle weakness or rhabdomyolysis between groups. Lipitor 80 mg is not a starting dose.

About Lipitor

Lipitor is extensively studied and the most prescribed cholesterol-lowering therapy in the world, with nearly 139 million patient-years of experience. Lipitor is supported by an extensive clinical trial program involving more than 400 ongoing and completed trials with more than 80,000 patients.

Important Safety Information

Lipitor is a prescription medication. It is used in patients with multiple risk factors for hear
'"/>




Page: 1 2 3

Related medicine technology :

1. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
2. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
3. Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
Post Your Comments:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: Germany ... 2020 http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- EDGE Orthopaedics, a new entry in ... announce they have received their second FDA 510(k) ... Fracture Plating System. The VIEW Plating ... indications within the mid-foot. The system includes titanium ... (CC), Talonavicular (TN) and Evans plates along with ...
(Date:8/28/2014)... CITY , Aug. 28, 2014 /PRNewswire-iReach/ -- Academy ... by service academy graduates, has published a case ... three-day Leadership Excellence Course . In September and ... Excellence Course to Albuquerque , Indianapolis ... . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... Cancer Journal , AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--Introgen,Therapeutics, ... the dramatic clinical benefit of its lead product,Advexin ... of cancer known as,Li-Fraumeni Syndrome (LFS), a genetic ... suppressor gene. This is the,first reported treatment of ...
... CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead,Sciences, ... III,AIR-CF1 (CP-AI-007) study of aztreonam lysine for ... fibrosis (CF) who have,pulmonary Pseudomonas aeruginosa (P. ... at Day 28 from baseline in respiratory,symptoms, ...
Cached Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
(Date:8/29/2014)... neuroregenerative effect, stimulating neurite extension in the ... and enhancing nerve regeneration following nerve crush ... FK506 to stimulate nerve regeneration is limited ... and hypertension, and its considerable cost. With ... other drugs reportedly cause life-threatening infections. Like ...
(Date:8/29/2014)... August 29, 2014 The Fresh Diet, ... introduce its new Fresh Vegetarian meal plan. Originating from ... meals, the new menu is designed to satisfy customers ... lifestyle. , Responding to the growing demand ... a multi-billion dollar market (Forbes) with 14% of Americans ...
(Date:8/29/2014)... 2014 Glendale Botox experts at ... Botox throughout the month of September. This special offer features ... syringes of Juvederm. Patients can take advantage of this special ... Glendale Botox experts will work with patients to determine if ... What is Botox? , Botox is a treatment made ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Researchers have ... in their brains. Dyslexia -- the most commonly ... problems with reading and writing. Previous research showed ... but most of those studies focused only on a ... used functional MRI to analyze how multiple brain regions ...
(Date:8/29/2014)... VA (PRWEB) August 29, 2014 For ... Research Foundation (Meso Foundation) will be observing September 26th ... on Rockefeller Plaza, in New York. , Members ... encouraged to RSVP . The Foundation will be providing ... the past years, mesothelioma community members have received attention ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Scientists Find Differences in Brains of Those With Dyslexia 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2
... A night of food and festivities for a great ... ActionAIDS has shown their appreciation for people who through ... a very real difference in the lives of men, ... recognizes those individuals with their highest honor: The ...
... structuring physician payment incentives around existing empirical evidence ... reduce the cost of healthcare, says a commentary ... Circulation: Cardiovascular Quality and Outcomes . ... suffering from mild chest pain due to coronary ...
... 20 Young Innovations, Inc. (Nasdaq: YDNT ) today ... a live and on-demand web cast conference call on Tuesday, April ... broadcast of the call will be available through InterCall at ... live audio broadcast will also be available through the Company,s website, ...
... Eli Lilly and Company (NYSE: LLY ) today ... $0.49 a share on outstanding common stock. This is ... and maintains the annual indicated dividend rate for 2009 of ... shareholders of record at the close of business on May ...
... (Nasdaq: AMGN ) today announced that it plans ... 23, 2009 after the close of the financial markets. The ... investment community at 2 p.m. Pacific Time. Participating in ... chief executive officer, and other members of Amgen,s senior management ...
... 8-ounce glass enhances absorption of rapamycin 3 to 4 times ... boosts the anti-cancer effects of the drug rapamycin, according to ... tumors, for which there is no effective treatment. , ... as a liquid, once a week. After the first week ...
Cached Medicine News:Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 2Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 3Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 4Health News:Health-care reform should start with paying evidence-based financial incentives to doctors 2Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Amgen Announces Webcast of 2009 First Quarter Financial Results 2Health News:Grapefruit Juice Boosts Anti-Cancer Drug's Effects 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: